End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.86 USD | -1.00% | +3.04% | +21.67% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+21.67% | 5.42B | B- | ||
+25.52% | 88.99B | C+ | ||
-24.52% | 74.82B | B- | ||
-2.54% | 25.03B | C+ | ||
+4.31% | 17.88B | A- | ||
-14.25% | 16.43B | B | ||
+2.97% | 15.77B | A- | ||
+79.20% | 13.21B | C+ | ||
+70.11% | 13.08B | C- | ||
+40.44% | 12.9B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RCM Stock
- Ratings R1 RCM Inc.